Résistance clinique au STI571 : implication du gène bcr-abl lui-même ?

Author： Mahon François-Xavier  

Publisher： Edp Sciences

E-ISSN： 1958-5381|17|11|1192-1193

ISSN： 0767-0974

Source： Médecine/sciences, Vol.17, Iss.11, 2010-10, pp. : 1192-1193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Regression der Philadelphia-Chromosom (bcr/abl)-positiven Myelo- und Megakaryopoiese unter Imatinib(STI571)-Therapie bei chronischer myeloischer Leukämie (CML)

By Thiele J.   Kvasnicka H.   Varus E.   Kriener S.   Engels K.   Staib P.   Ollig E.   Griesshammer M.   Waller C.   Pfeifer H.   Schmitt-Gräff A.  

Der Pathologe, Vol. 25, Iss. 6, 2004-11 ,pp. : 428-436

Springer Publishing Company

Access to resources Recommend Favorite

Anticipating Clinical Resistance to Target-Directed Agents: The BCR-ABL Paradigm

By Azam Mohammad   Daley George Q.  

Molecular Diagnosis & Therapy, Vol. 10, Iss. 2, 2006-01 ,pp. : 67-76

Adis International

Access to resources Recommend Favorite

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

By Razga Filip   Jurcek Tomas   Zackova Daniela   Dvorakova Dana   Toskova Martina   Jeziskova Ivana   Mayer Jiri   Racil Zdenek  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

Acute Lymphoblastic Leukaemia with an e1a3 BCR-ABL1 Fusion

By  

Acta Haematologica, Vol. 126, Iss. 4, 2011-09 ,pp. : 214-215

Karger

Access to resources Recommend Favorite

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

By  

Acta Haematologica, Vol. 119, Iss. 4, 2008-06 ,pp. : 212-217

Karger

Access to resources Recommend Favorite